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Abstract: The authors tested the 
hypothesis that obstructive sleep 
apnea (OSA) signs/symptoms are 
associated with the occurrence of 
temporomandibular disorder (TMD), 
using the OPPERA prospective cohort 
study of adults aged 18 to 44 years 
at enrollment (n = 2,604) and the 
OPPERA case-control study of chronic 
TMD (n = 1,716). In both the OPPERA 
cohort and case-control studies, TMD 
was examiner determined according 
to established research diagnostic 
criteria. People were considered to 
have high likelihood of OSA if they 
reported a history of sleep apnea or 
≥ 2 hallmarks of OSA: loud snoring, 
daytime sleepiness, witnessed apnea, 
and hypertension. Cox proportional 
hazards regression estimated hazard 
ratios (HRs) and 95% confidence 
limits (CL) for first-onset TMD. Logistic 
regression estimated odds ratios (OR) 
and 95% CL for chronic TMD. In the 
cohort, 248 individuals developed first-
onset TMD during the median 2.8-
year follow-up. High likelihood of OSA 
was associated with greater incidence 
of first-onset TMD (adjusted HR = 
1.73; 95% CL, 1.14, 2.62). In the case-
control study, high likelihood of OSA 
was associated with higher odds of 
chronic TMD (adjusted OR = 3.63; 95% 
CL, 2.03, 6.52). Both studies supported 
a significant association of OSA 
symptoms and TMD, with prospective 
cohort evidence finding that OSA 
symptoms preceded first-onset TMD.
Key Words: chronic pain, 
epidemiology, cohort studies, case-
control studies, sleep-disordered 
breathing, autonomic effect. 
Introduction
Thirty percent of US adults have pain 
persisting for 6 mos or longer ( Johannes 
et al., 2010). Experimental studies 
involving humans have established 
that pain and sleep disruption occur 
in reciprocal, bidirectional relations. 
Experimentally reducing total sleep 
and disrupting slow-wave and rapid-
eye-movement stages of sleep evoke 
musculoskeletal pain (Moldofsky, 2008), 
decreased pain thresholds, increased 
pain sensitivity (Onen et al., 2001), 
and lowered antinociceptive potency 
of morphine (Skinner et al., 2011). 
Reciprocally, when individuals with 
excessive daytime sleepiness due to sleep 
deprivation extended their sleep, their 
finger withdrawal latency to noxious heat 
increased by 25% (Roehrs et al., 2012).
Sleep extension, however, does not 
restore sleep quality in sleep-disordered 
breathing. During sleep, neuronal 
activation of dilator muscles that maintain 
airway patency during wakefulness 
is reduced. In individuals with excess 
pharyngeal fat deposits or structural 
anatomic abnormalities that encroach on 
airway diameter, this loss of compensatory 
tonic input results in repetitive episodes 
of upper airway collapse. In people with 
obstructive sleep apnea (OSA), the upper 
airway obstruction causes respiratory 
hypopneas (reductions) or apneas 
(pauses), despite persisting respiratory 
efforts that terminate when central nervous 
system arousal restores airway patency. 
The immediate effects are oxyhemoglobin 
desaturation, blood pressure and heart 
rate fluctuations, sustained sympathetic 
excitation, cortical arousal, and sleep 
fragmentation. Long-term effects include 
neurocognitive impairment (Lal et al., 
2012), metabolic syndrome (Hasan et al., 
2012), systemic hypertension (Peppard 
et al., 2000), and cardiovascular diseases 
(Redline et al., 2010).
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OSA is estimated to affect 4% of men 
and 2% of women (Young et al., 1993) 
and accounts for 95% of all apneas. Nasal 
continuous positive airway pressure (CPAP) 
is effective in maintaining airway patency 
in OSA, as are oral appliances that hold the 
jaw in a forward position. Both therapies 
reduce blood pressure (Gotsopoulos et al., 
2002), and CPAP decreases pain sensitivity 
(Khalid et al., 2011) and increases pain 
tolerance (Onen et al., 2010).
An emergent body of evidence suggests 
that OSA is associated with chronic pain 
disorders including temporomandibular 
disorder (TMD) (Cunali et al., 2009; Smith 
et al., 2009). TMD is a musculoskeletal 
disorder characterized by persistent 
pain in the temporomandibular joint, 
periauricular region, and masticatory 
muscles. Current evidence of a 
relationship between OSA and TMD is 
limited to descriptive findings in clinical 
samples (Cunali et al., 2009; Smith et al., 
2009) that, while suggestive of association, 
cannot estimate strength of association 
or determine the temporal order of the 
association between OSA and pain.
To extend this preliminary evidence, 
the authors estimated the strength of 
association between OSA signs/symptoms 
and chronic TMD in a population-based 
epidemiologic study of TMD. We tested 
the hypothesis that OSA sign/symptoms 
are associated with the occurrence of 
TMD and precede first-onset TMD.
Methods
Institutional review boards at each of 
4 study sites and the data coordination 
center granted approval for study 
procedures, and participants provided 
informed consent.
Study Design and Recruitment
The Orofacial Pain Prospective Evaluation 
and Risk Assessment study (OPPERA) is 
a prospective cohort study designed to 
investigate the etiology of first-onset TMD. 
Its detailed methodology is described 
elsewhere (Slade et al., 2011). Briefly, from 
2002 to 2004, 3,263 adults were recruited 
by community-wide advertising at 4 US 
study sites: Baltimore, Maryland; Buffalo, 
New York; Chapel Hill, North Carolina; 
and Gainesville, Florida. Eligibility criteria 
were: age 18 to 44 yrs, good health, no 
history of facial injury or surgery, no 
significant symptoms of TMD pain, no 
previous diagnosis of TMD, and an absence 
of TMD myalgia and TMD arthralgia on 
clinical examination. The target sample 
size of 3,200 was expected to yield 196 
cases of first-onset TMD, assuming 30% 
loss to follow-up, sufficient to address 
study aims regarding the incidence 
and etiology of TMD. Once enrolled, 
participants completed quarterly screening 
questionnaires to monitor the development 
of TMD symptoms. Symptomatic 
participants were recalled for examination 
to establish a definitive classification of 
incident TMD.
A case-control study of chronic TMD 
was embedded in OPPERA at baseline. 
Chronic cases were adults aged 18 to  
44 yrs, with TMD symptomatic for at least  
6 mos (n = 182), recruited by community-
wide advertising at the same study sites. 
Controls were a random sample of 
enrollees in the cohort study (n = 1,534). 
All cohort and case-control participants 
completed health-history questionnaires 
and a three-hour clinical assessment 
that included physical examination 
and assessment of autonomic function. 
OPPERA’s unique hybrid design permitted 
rigorous comparison of chronic TMD 
vs. incident first-onset TMD phenotypes 
under standardized conditions.
TMD Classification
All participants were clinically examined 
according to Research Diagnostic Criteria 
for TMD (RDC/TMD) (Dworkin and 
LeResche, 1992) adapted for OPPERA. 
TMD cases met 2 criteria: (1) ≥ 5 days/
month of pain in masticatory structures, 
confirmed by examiner; and (2) examiner 
findings of arthralgia [i.e., pain in 
temporomandibular joint(s) during jaw 
maneuver or digital palpation] and/or 
myalgia (i.e., pain during jaw maneuver 
or digital palpation in ≥ 3 of 8 muscle 
groups based on bilateral assessment of 




From the Pittsburgh Sleep Quality Index 
(PSQI), we extracted responses to 3 
questions that asked about loud snoring, 
trouble staying awake, and witnessed 
apnea. From the medical history, we 
extracted hypertension information. 
Together, these 4 hallmarks of OSA 
comprise the 4-item OSA screening 
questionnaire called STOP that was 
validated against polysomnography 
(Chung et al., 2008). STOP was 
developed to identify individuals likely 
to have OSA, so that special precautions 
could be taken during/after general 
anesthesia. Affirmative responses to 
≥ 2 of these questions indicated high 
likelihood for OSA. We adopted this 
scoring convention, and, consistent with 
the scoring of STOP, we defined  
≥ 2 affirmative responses to these signs/
symptoms as indicative of high likelihood 
of OSA. In addition, people with a self-
reported history of sleep apnea were 
classified as having high likelihood for 
OSA, regardless of their responses to the 
four approximated STOP questions.
Autonomic Parameters
Sympathetic nerve activity and arterial 
pressure are commonly elevated among 
people with OSA (Leuenberger et al., 
2005). To explore the potential role of 
autonomic regulation, we measured 
arterial blood pressure and heart rate 
during 20 min of rest, using a blood 
pressure cuff. Average resting heart rate 
variability was measured with a 3-lead 
electrocardiogram to provide indirect 
measures of baroreflex sensitivity, 
described elsewhere (Maixner et al., 2011).
Covariates
Demographic characteristics were 
gender, age, race and ethnicity (White, 
African American, Asian, Hispanic). 
Standardized equipment measured height 
and weight to compute body mass index 
(BMI = weight/height2). Since cigarette 
smoking is associated with TMD (Sanders 
et al., 2012) and OSA, we classified 
smoking history as never smoked, former 
smoker, or current smoker. Subjective 
sleep quality was assessed with one item 
in the PSQI.
Statistical Analysis
Statistical analyses were conducted 
with SAS 9.2 (SAS Institute Inc., Cary, NC, 
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Table 1.
Associations of Baseline Characteristics of Participants with Signs/Symptoms of Obstructive Sleep Apnea (OSA) and Hazard Ratios for 
First-onset Temporomandibular Disorder (TMD), OPPERA Prospective Cohort Study (n = 2,604), 2006-2011
Characteristic N Column Percent
% at High Risk  
for OSA(a)
Rate of First-
onset TMD  
(% per annum)
Site-adjusted 
Hazard ratio  
(95% CL) for 
TMD(b)
Likelihood of OSA(a)
 Low 2,445 93.9 n/a 3.02 Referent
 High 159 6.1 n/a 6.96 2.29 (1.54, 3.42)
Gender
 Male 1,057 40.6 7.7 2.72 Referent
 Female 1,547 59.4 5.0 3.59 1.32 (1.02, 1.72)
Age group (yrs)
 18–24 1,370 52.6 3.1 2.47 Referent
 25–34 702 27.0 5.8 3.73 1.55 (1.14, 2.09)
 35–44 532 20.4 14.1 4.34 1.81 (1.29, 2.54)
Race/ethnicity
 White 1,397 53.7 4.5 2.98 Referent
 African American 700 26.9 11.4 4.79 1.58 (1.16, 2.15)
 Hispanic 249 9.6 1.6 1.05 0.35 (0.17, 0.71)
 Asian 172 6.6 3.5 2.89 0.96 (0.59, 1.57)
 Other/multiple/not stated 86 3.3 7.0 1.90 0.65 (0.27, 1.60)
Mean arterial pressure (mm Hg)(c)
 < 75 435 16.7 2.8 2.40 Referent
 75- < 80 597 22.9 5.7 2.82 1.18 (0.73, 1.58)
 80- < 85 672 25.8 4.6 3.31  1.39 (0.93, 1.98)
 >85 900 34.6 9.1 3.87 1.62 (1.07, 2.21)
Heart rate (beats per min)
 < 55 609 23.4 4.9 2.58 Referent
 55–61.9 675 25.9 4.6 2.77 1.07 (0.75, 1.83)
 62–68.9 628 24.1 6.5 3.55 1.36 (0.91, 2.13)
 >69.0 692 26.6 8.2 3.99 1.54 (1.09, 2.42)
Body mass index (kg/m2)
 Underweight/normal (< 25) 1,409 54.1 3.1 2.97 Referent
 Overweight (25– < 30) 712 27.3 7.0 2.60 0.87 (0.64, 1.20)
 Obese (≥ 30) 483 18.6 13.7 4.96 1.68 (1.24, 2.27)
Smoking history
 Never 1,973 75.8 4.4 2.51 Referent
 Former 224 8.6 9.4 5.76 2.33 (1.62, 3.34)
 Current 407 15.6 12.5 5.45 2.15 (1.54, 2.99)
PSQI(d) subjective sleep quality
 Very good 759 29.2 3.0 2.68 Referent
 Fairly good 1,444 55.5 5.6 2.89 1.07 (0.79, 1.46)
 Fairly bad and very bad 401 15.4 13.7 5.74 2.11 (1.49, 3.00)
(a) High likelihood of OSA defined as ≥ 2 affirmative responses to 4 questions that approximate the STOP screening questionnaire for OSA, or a self-reported history 
of sleep apnea.
(b) From Cox regression model controlling for OPPERA study site.
(c) Millimeters of mercury.
(d) Pittsburgh Sleep Quality Index item #6: During the past month, how would you rate your sleep quality overall?
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USA). Of the 3,258 people enrolled in 
the OPPERA cohort, this analysis omitted 
participants with missing follow-up data 
(n = 521), missing OSA classification  
(n = 1), or missing covariates (n = 132), 
yielding a sample size of 2,604. A Cox 
proportional hazard models estimated 
hazard ratios (HR) and 95% confidence 
limits (CL) to approximate the incidence 
rate ratio of first-onset TMD. Unlike odds 
ratios used for case-control studies where 
there is no time element, hazard ratios 
are appropriate for prospective cohort 
studies, since they take into account the 
length of time during which TMD-free 
participants are “at risk” of developing 
TMD. The exposure of interest was 
binary: low or high likelihood for OSA.
Recognizing that OSA signs/symptoms 
and TMD might have common contributing 
factors, we created 3 successive 
multivariable Cox models to determine the 
degree to which the OSA-TMD relationship 
was independent of those contributing 
factors: model 1 adjusted for study site 
and demographic characteristics; model 2 
added autonomic parameters; and model 
3 added BMI and smoking history. In the 
prospective cohort, mean site-adjusted and 
fully adjusted values of baseline resting 
autonomic parameters were examined 
against the summary OSA likelihood 
classification. Least-squares means were 
contrasted to determine the statistical 
significance of differences in mean 
autonomic measures between/among OSA 
symptom groups.
Excluded from the 1,818 people in the 
OPPERA case control study were people 
missing an OSA classification (n = 1) 
or missing covariates (n = 101), for a 
sample size of 1,716. Odds ratios (ORs) 
and 95% confidence limits (CL) were 
estimated by binary logistic regression. 
As with the cohort analysis, multivariate 
logistic regression adjusted for potential 
confounding in the same three-staged 
manner.
Regression models subsequently tested 
the effect of further adjustment for 
subjective sleep quality to investigate 
whether an association between OSA 
likelihood and TMD was independent of 
sleep quality.
Results
Within the prospective cohort, 248 
people developed first-onset TMD in 
7,068 person-years of follow-up, yielding 
an average annual incidence rate of 
3.5% in this analysis. Among the 6.1% 
of people with high likelihood for OSA, 
the rate of first-onset TMD was two-fold 
greater relative to that of people with low 
likelihood for OSA (site-adjusted HR = 
2.29 [95% CL: 1.54, 3.42]) (Table 1).
Other putative predictors were female 
gender, older age, African-American race, 
obesity, cigarette smoking, and poor self-
rated sleep quality. Incidence of first-
onset TMD increased across successive 
categories of mean arterial pressure and 
mean heart rate in a monotonic fashion.
Adjustment for confounding (Table 2) 
attenuated the strength of association 
between high likelihood of OSA and first-
onset TMD. The association remained 
statistically significant, with 73% higher 
incidence of TMD among people with 
high likelihood for OSA (HR = 1.73; 95% 
CL, 1.14, 2.62).
Table 2.
Multivariable Model Showing Hazard Ratios (95% confidence limits) for Incident First-onset TMD, OPPERA Prospective Cohort (n =2,604), 
2006-2011
Model 1 HR (95%CL) Model 2 HR (95%CL) Model 3 HR (95%CL)
High likelihood of obstructive sleep apnea (a) 1.90 (1.26, 2.87) 1.85 (1.22, 2.79) 1.73 (1.14, 2.62)
Gender, female [ref = male] 1.30 (1.00, 1.69) 1.29 (0.99, 1.69) 1.31 (1.00, 1.72)
Age in yrs/10 1.21 (1.01, 1.44) 1.17 (0.98, 1.41) 1.05 (0.86, 1.27)
Race/ethnicity African American [ref = White] 1.38 (1.01, 1.90) 1.29 (0.93, 1.79) 1.32 (0.94, 1.85)
Race/ethnicity Hispanic [ref = White] 0.37 (0.18, 0.76) 0.37 (0.18, 0.76) 0.39 (0.19, 0.80)
Race/ethnicity Asian [ref = White] 0.99 (0.61, 1.62) 0.98 (0.60, 1.60) 0.96 (0.59, 1.57)
Race/ethnicity Other [ref = White] 0.62 (0.25, 1.52) 0.61 (0.25, 1.50) 0.66 (0.27, 1.62)
Average resting heart rate (bpm/10) 1.07 (0.94, 1.21) 1.04 (0.92, 1.18)
Average resting mean arterial blood pressure (mm Hg/10) 1.11 (0.95, 1.29) 1.08 (0.92, 1.25)
BMI overweight [ref = underweight/normal] 0.78 (0.56, 1.08)
BMI obese [ref = underweight/normal] 1.21 (0.87, 1.70)
Smoking history: Former [ref = Never] 2.20 (1.51, 3.21)
Smoking history: Current [ref=Never] 1.81 (1.27, 2.57)
(a) High likelihood of OSA is a summary variable derived from ≥ 2 affirmative responses to four questions that approximate items in the STOP screening 
questionnaire for OSA or self-reported history of sleep apnea.
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Table 3.
Odds Ratios (OR) for Chronic Temporomandibular Disorder (TMD), OPPERA Case Control Study (n = 1,716), 2006-2008
N % OR (95%CL)
Likelihood of OSA (a)
 Low 1,614 94.1 Referent
 High 102 5.9 2.98 (1.77, 5.00)
Gender
 Male 687 40.0 Referent
 Female 1,029 60.0 3.80 (2.53, 5.71)
Age group (yrs)
 18-24 876 51.1 Referent
 25-34 480 28.0 1.70 (1.17, 2.48)
 35-44 360 21.0 2.24 (1.46, 3.43)
Race/ethnicity
 White 909 53.0 Referent
 African American 474 27.6 2.15 (1.29, 3.57)
 Hispanic 157 9.2 3.99 (2.28, 7.00)
 Asian 123 7.2 2.35 (1.41, 3.93)
 Other/multiple/not stated 53 3.1 0.21 (0.13, 0.35)
Mean arterial pressure (mm Hg)
 < 75 619 36.1 Referent
 75- < 80 274 16.0 1.33 (0.78, 2.27)
 80- < 85 392 22.8 1.08 (0.63, 1.86)
 >85 431 25.1 1.54 (0.94, 2.52)
Mean heart rate (bpm)
 < 55 397 23.1 Referent
 55-61.9 433 25.2 1.25 (0.77, 2.02)
 62-68.9 408 23.8 1.36 (0.84, 2.20)
 >69.0 478 27.9 1.88 (1.20, 2.95)
Body mass index (kg/m2) 
 Underweight/normal (< 25) 888 51.8 Referent
 Overweight (25- < 30) 490 28.6 0.82 (0.57, 1.19)
 Obese (> = 30) 338 19.7 0.90 (0.59, 1.36)
Smoking history
 Never 1,244 72.5 Referent
 Former 160 9.3 2.28 (1.47, 3.53)
 Current 312 18.2 0.76 (0.46, 1.24)
PSQI subjective sleep quality (b)
 Very good 487 28.4 Referent
 Fairly good 925 53.9 2.03 (1.30, 3.17)
 Fairly bad and very bad 304 17.7 4.46 (2.75, 7.24)
(a) High likelihood of OSA is a summary variable derived from ≥ 2 affirmative responses to 4 questions that approximate items in the STOP screening questionnaire 
for OSA or self-reported history of sleep apnea.
(b) Pittsburgh Sleep Quality Index item #6: During the past month, how would you rate your sleep quality overall?
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Table 4.
Multivariable Model Showing Odds Ratios (95% confidence limits) for Chronic TMD, OPPERA Case Control Study (n = 1,716), 2006-2008
Model 1  
OR (95%CL)
Model 2  
OR (95%CL)
Model 3  
OR (95%CL)
High likelihood of obstructive sleep apnea (a) 3.48 (1.95, 6.19) 3.34 (1.87, 5.96) 3.63 (2.03, 6.52)
Gender, female [ref = male] 4.07 (2.67, 6.19) 4.08 (2.66, 6.26) 3.96 (2.58, 6.08)
Age in yrs/10 (b) 1.57 (1.26, 1.95) 1.48 (1.18, 1.86) 1.49 (1.17, 1.88)
Race/ethnicity African American [ref = White] 0.16 (0.10, 0.28) 0.14 (0.08, 0.25) 0.16 (0.09, 0.28)
Race/ethnicity Hispanic [ref = White] 0.29 (0.12, 0.68) 0.30 (0.13, 0.70) 0.30 (0.13, 0.72)
Race/ethnicity Asian [ref = White] 0.58 (0.30, 1.11) 0.57 (0.30, 1.09) 0.59 (0.31, 1.13)
Race/ethnicity Other [ref = White] 0.34 (0.11, 1.01) 0.33 (0.11, 0.99) 0.35 (0.12, 1.06)
Average resting heart rate (bpm/10) (c) 1.14 (0.97, 1.35) 1.16 (0.98, 1.37)
Average resting mean arterial blood pressure (mm Hg/10) (d) 1.20 (0.97, 1.48) 1.22 (0.98, 1.51)
BMI overweight [ref = underweight/normal] 0.88 (0.59, 1.31)
BMI obese [ref = underweight/normal] 0.84 (0.52, 1.36)
Smoking history: Current [ref = Never] 1.60 (0.99, 2.59)
Smoking history: Former [ref = Never] 0.68 (0.40, 1.16)
(a) High likelihood of OSA is a summary variable derived from ≥ 2 affirmative responses to 4 questions that approximate items in the STOP screening questionnaire 
for OSA or a self-reported history of sleep apnea.
(b) Age in yrs scaled to decades.
(c) Mean heart rate scaled to units of 10 beats.
(d) Mean arterial pressure scaled to units of 10 mm Hg.
In the case-control study of chronic 
TMD (Table 3), 5.9% of participants  
(n = 102) had high likelihood for OSA. 
Compared with controls, chronic TMD 
cases had three-fold greater odds of high 
likelihood for OSA (site-adjusted OR = 
2.98; 95% CL, 1.77, 5.00). Adjustment 
for potential confounders (Table 4) 
strengthened the association (OR = 3.63; 
95% CL, 2.03, 6.52).
Subsequent adjustment for subjective 
sleep quality further attenuated 
associations between OSA symptoms and 
TMD in both the cohort (HR = 1.52; 95% 
CL, 1.00, 2.31) and the case-control study 
(OR = 2.62; 95% CL, 1.43, 4.79) (not 
tabulated).
In the prospective cohort, high 
likelihood for OSA was significantly 
associated with elevated baseline mean 
arterial pressure and mean heart rate, and 
with lower baseline standard deviation 
of normal-to-normal intervals (Appendix 
Table 1). Only mean heart rate remained 
significantly associated with OSA risk 
after adjustment for all covariates.
Discussion
Key Findings
In the population-based cohort of 
adults free of TMD at baseline, OSA 
signs/symptoms were associated with 
increased incidence of first-onset TMD. 
Men and women with 2 or more signs/
symptoms of OSA had 73% greater 
incidence of first-onset TMD, in relative 
terms, than those with fewer signs/
symptoms, independently of age, gender, 
race/ethnicity, obesity, smoking history, 
and autonomic parameters. In the case-
control study, chronic TMD was more 
than 3 times as frequent among adults 
with low relative to high likelihood 
of OSA, independently of these same 
factors. In both studies, the effects of 
high likelihood of OSA were independent 
of sleep quality.
Comparison with Previous Findings
Earlier studies of OSA and TMD, 
conducted in unrepresentative clinic 
samples without a comparison group, 
were nonetheless informative because 
of the inclusion of in-laboratory 
polysomnographic recordings. Among 87 
adults diagnosed by polysomnography 
as having mild or moderate OSA, 32 
(36.8%) had TMD determined by RDC/
TMD criteria (Cunali et al., 2009). In 
another study, 11 adults (28%) of 53 
with RDC/TMD-based myofascial pain 
were diagnosed by polysomnography 
as having OSA (Smith et al., 2009). 
OPPERA’s population-based studies 
extend these case series reports by 
quantifying the strength of association 
and demonstrating that OSA symptoms 
are associated with both first-onset TMD 
and chronic TMD. This study’s findings of 
an association between OSA symptoms 
and TMD contribute to a growing body 
of evidence documenting a relationship 
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between sleep-disordered breathing 
and other idiopathic pain conditions, 
including fibromyalgia (Moldofsky et al., 
1975), irritable bowel syndrome (Rotem 
et al., 2003), and headache (Rains and 
Poceta, 2012).
One mechanism by which SDB may 
contribute to pain over time is through 
the effect of central sensitization and 
pain amplification in decreasing function 
in pain inhibitory systems (Smith et al., 
2007), for example, via baroreceptor 
pathways. Experimental inspiratory 
resistance reduces baroreceptor reflex 
sensitivity in humans, and impaired 
baroreceptor reflex sensitivity is 
implicated in TMD (Maixner et al., 1997). 
It is also possible that the increased 
stimulation of the sympathetic nervous 
system observed in OSA underlies an 
increased prevalence of TMD: Individuals 
who are genetically predisposed to an 
increased sensitivity to catecholamines 
are at increased risk of developing first-
onset TMD (Diatchenko et al., 2005). 
Third, although a causal association 
remains controversial (Manfredini et al., 
2012), bruxism—which is more common 
in people with OSA than in those without 
OSA (Ohayon et al., 2001)—may be 
implicated in TMD development.
Strengths and Limitations
Strengths of the study include the 
prospective cohort design, which 
established the presence of OSA signs/
symptoms prior to first-onset TMD, the 
rigorous OPPERA protocols, and the 
rich OPPERA dataset. Both the cohort 
and case-control studies were large and 
population-based, with statistical power 
to detect small effects. Multiple study sites 
and community recruitment optimized 
the diversity and representativeness of 
the study population to improve the 
generalizability of findings. Although 
causality cannot be inferred from 
observational data alone, the prospective 
cohort findings imply that OSA 
contributes to the onset of painful TMD 
symptoms. Our adjustment for subjective 
sleep quality in analytic models 
constitutes “over-adjustment”, because 
poor sleep quality is a consequence both 
of pain and of the fragmented sleep 
evoked by sleep-disordered breathing. 
Over-adjustment tends to bias results 
toward the null. Instead, our purpose in 
adjusting for subjective sleep quality was 
to demonstrate that our main exposure–
OSA symptomatology–was independently 
associated with TMD rather than merely 
a proxy of sleep quality. Even with this 
excessively conservative approach, OSA 
symptoms remained a significant factor.
The gold-standard for OSA diagnosis is 
laboratory polysomnography. The STOP 
has sensitivity of 0.66 and specificity of 
0.60 to classify OSA in adults without 
history of sleep disorders (Chung et al., 
2008) and inevitably misclassifies OSA 
risk. However, since there is no reason 
for misclassification to differ between 
TMD cases and non-cases, resulting 
bias will shift estimates of association 
conservatively toward the null.
The strength of association between 
OSA signs/symptoms and TMD may 
be underestimated in this young 
OPPERA population. It is likely that the 
relationship between OSA and TMD is 
stronger among older adults, especially 
those with co-morbid conditions, 
including obesity.
Missing data arising from loss to 
follow-up poses a major threat to validity 
in prospective cohort studies. We did 
not impute values for participants lost 
to follow-up or data missing through 
non-report. This decision was justified 
because our multiple imputation 
techniques and sensitivity analyses 
showed that doing so did not appreciably 
change the incidence rate (Bair et al., 
manuscript under review). 
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